Continuous Glucose Monitors:
HB 1465 requires the Florida Agency for Health Care Administration to seek federal approval within 30 days to cover continuous glucose monitors and related supplies under Medicaid as durable medical equipment. The bill directs the agency to use a Medicaid waiver or state plan amendment if needed, and to reimburse licensed durable medical equipment providers for these items when claims are submitted using an active Medicare HCPCS code. It also prohibits the agency from requiring a National Drug Code on those claims.
The bill does not bar Florida from also covering continuous glucose monitors through the Medicaid pharmacy benefit, and it requires implementation once any necessary federal approval is obtained. In practical terms, the measure would expand and clarify Medicaid coverage for diabetes monitoring technology, potentially improving access for eligible recipients who need continuous glucose monitors and related supplies.
If enacted, the bill would amend how Florida Medicaid covers continuous glucose monitors by treating them as durable medical equipment and requiring AHCA to pursue federal approval to make that coverage available. It would affect Medicaid recipients, durable medical equipment providers, and the state agency responsible for administering Medicaid claims and reimbursement rules. The bill also changes billing requirements by allowing reimbursement through HCPCS coding and prohibiting an NDC requirement for these claims, while preserving the option for separate pharmacy-benefit coverage.
The available context suggests the bill was generally favorable in concept, as it sought to expand access to a diabetes management device used by many Medicaid enrollees. However, the bill ultimately died in the Health & Human Services Committee, indicating it did not advance through the legislative process. No committee transcript or recorded votes were provided, so the broader discussion and level of support or opposition cannot be assessed in detail from the available record.
The main policy issue appears to be the mechanism for coverage and reimbursement rather than whether continuous glucose monitors are beneficial. Potential points of contention include whether Medicaid should cover the devices as durable medical equipment versus a pharmacy benefit, whether AHCA should be required to seek federal approval on a fixed timeline, and whether billing rules should exclude an NDC requirement. Because no committee transcripts or votes are available, it is not possible to identify specific legislators, agencies, or stakeholder groups that raised objections.